this is a slide share showing an example of a drug profile , this helps students to make a drug documentation suitably. here an example of Rhopressa (netarsudil ophthalmic solution) drug profile has given below please comment thank u

1. DRUG DOCUMENTATION.
(A SAMPLE FOR REFERENCE & STUDY)/
HOW TO DO A DRUG PROFILE/ DOCUMENTATION FOR ACADEMIC
PURPOSE?
PRESENTED BY
MARTIN SHAJI
PHARM D

2. DRUG
DOCUMENTATION.
Rhopressa (netarsudil ophthalmic solution)
Rhopressa is specifically indicated for the reduction of
elevated intraocular pressure (IOP) in patients with open-
angle glaucoma or ocular hypertension.1

3. 2. Chemistry & details of drug
GENERIC NAME; netarsudil ophthalmic solution.
BRAND NAME; Rhopressa.
APPROVAL STATUS; Approved on 2018
CATEGORY; Ophthalmic drug.
DOSAGE; Ophthalmic solution.(eye drop)
DOSE; 4drops BID

4. THERAPEUTIC AREA; Ophthalmology.
SPECIFIC TREATMENT; reduction of elevated intraocular
pressure (IOP) in patients with open-angle glaucoma or ocular
hypertension.
CHEMICAL STRUCTURE;

5. 3.CLINICAL PHARMACOLOGY.
Mechanism of Action
Rhopressa (netarsudil ophthalmic solution) is a Rho kinase
inhibitor, which is believed to reduce IOP by increasing the
outflow of aqueous humor through the trabecular meshwork
route. The exact mechanism is unknown.

6. Side Effects
Adverse effects associated with the use of Rhopressa may include, but are
not limited to, the following:
 conjunctival hyperemia
 corneal verticillata
 instillation site pain
 conjunctival hemorrhage
INDICATION.
Rhopressa is specifically indicated for the reduction of elevated intraocular
pressure (IOP) in patients with open-angle glaucoma or ocular
hypertension

7. DRUG CLASS.
Rho kinase inhibitor.
CONTRAINDICATIONS.
Bacterial Keratitis - There have been reports of bacterial keratitis
associated with the use of multiple-dose containers of topical
ophthalmic products. These containers had been inadvertently
contaminated by patients who, in most cases, had a concurrent
corneal disease or a disruption of the ocular epithelial surface

8. ADVERSE DRUG REACTIONS..
RHOPRESSA® dosed once daily was conjunctival hyperemia which
was reported in 53% of patients. Other common (approximately 20%)
adverse reactions were: corneal verticillata, instillation site pain, and
conjunctival hemorrhage. Instillation site erythema, corneal staining,
blurred vision, increased lacrimation, erythema of eyelid, and reduced
visual acuity were reported in 5-10% of patients.
4. Overdose
This medicine may be harmful if swallowed. If someone has
overdosed and has serious symptoms such as passing out
or trouble breathing

9. IMPORTANT SAFETY INFORMATION
Dosage and Administration: Twice a day dosing is not well
tolerated and is not recommended. If RHOPRESSA® is to be
used concomitantly with other topical ophthalmic drug products
to lower IOP, administer each drug product at least 5 minutes
apart.

10. More Information
Rhopressa is supplied as a solution for ophthalmic
administration. The recommended dosage is one drop in the
affected eye(s) once daily in the evening. If one dose is
missed, treatment should continue with the next dose in the
evening. Twice a day dosing is not well tolerated and is not
recommended. If Rhopressa is to be used concomitantly with
other topical ophthalmic drug products to lower IOP, administer
each drug product at least 5 minutes apart.

11. PHARMACOKINETICS.
It follows normal ocular pharmacokinetics ,and not yet well
defined.
REFERENCE.
BNF(1&2), LXICOMP(3&4)

12. THANK YOU